Blog
RSS FeedPosted by Michael Wonder on 09 Jun 2021
Paladin Labs announces approval of Wakix (pitolisant) in Canada
9 June 2021 - Paladin Labs today announced Health Canada's approval of Wakix (pitolisant) for the treatment of excessive daytime sleepiness ...
Posted by Michael Wonder on 08 Jun 2021
Health Canada approves AbbVie's Rinvoq (upadacitinib) for the treatment of adults with active psoriatic arthritis
7 June 2021 - Approval supported by efficacy and safety data of two pivotal Phase 3 trials in which Rinvoq demonstrated ...
Posted by Michael Wonder on 02 Jun 2021
Health Canada approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as the first and only immunotherapy treatment for previously untreated unresectable malignant pleural mesothelioma
2 June 2021 - First new systemic therapy in more than 15 years for cancer related to asbestos exposure. ...
Posted by Michael Wonder on 01 Jun 2021
Health Canada approves Abecma (idecabtagene vicleucel), the first and only anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma
31 May 2021 - Abecma is the first personalised cell therapy available to Canadian patients for the treatment of adults ...
Posted by Michael Wonder on 06 May 2021
Health Canada issues Notice of Compliance for Bausch Health's Bryhali
5 May 2021 - Bausch Health Canada today announced that Health Canada has approved the use of Bryhali (halobetasol propionate 0.01% ...
Posted by Michael Wonder on 30 Apr 2021
Ilaris receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease
29 April 2021 - The approval of Ilaris (canakinumab) in the treatment of adult-onset Still's disease brings hope for Canadians living ...
Posted by Michael Wonder on 28 Apr 2021
Rockwell Medical announces marketing approval of Triferic AVNU in Canada
27 March 2021 - Rockwell Medical today announced that Triferic AVNU (ferric pyrophosphate citrate injection) received a Notice of Compliance (marketing ...
Posted by Michael Wonder on 23 Apr 2021
AbbVie receives Health Canada approval of Humira (adalimumab) for the treatment of paediatric patients with moderately to severely active ulcerative colitis
22 April 2021 - Approval based on results from the pivotal Phase 3 ENVISION I trial, the largest clinical trial in ...
Posted by Michael Wonder on 19 Apr 2021
Darzalex SC becomes the first and only Health Canada approved treatment for patients with newly diagnosed light chain amyloidosis, a rare disease
19 April 2021 - Darzalex SC combination regimen is supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher haematologic ...
Posted by Michael Wonder on 17 Apr 2021
Health Canada authorises Evrysdi (risdiplam) for the treatment of spinal muscular atrophy in adults and children
15 April 2021 - Evrysdi (risdiplam) is the first at home administered treatment for spinal muscular atrophy. ...
Posted by Michael Wonder on 08 Apr 2021
Teva Canada announces new auto-injector for Ajovy for the preventive treatment of migraine in adults
8 April 2021 - Ajovy now offers patients greater flexibility with two dosing options available in both an auto-injector and a ...
Posted by Michael Wonder on 03 Apr 2021
Taltz (ixekizumab) approved by Health Canada for the treatment of paediatric patients (six to less than 18 years of age) with moderate to severe plaque psoriasis
2 April 2021 - On 29 March 2021, Health Canada issued a Notice of Compliance for Taltz (ixekizumab) injection, 80 mg/mL, ...
Posted by Michael Wonder on 24 Mar 2021
Seqirus ready to reinforce Canada's influenza pandemic preparedness plans
23 March 2021 - Health Canada's approval of Foclivia (an adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine) meets key requirement ...
Posted by Michael Wonder on 23 Mar 2021
Health Canada approves Kesimpta, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis
23 March 2021 - Approval is based on two Phase 3 studies (ASCLEPIOS I & II) demonstrating significant reductions in risk ...
Posted by Michael Wonder on 19 Mar 2021
Seqirus announces Health Canada approval of expanded age indication of its cell-based quadrivalent influenza vaccine for people two years of age and older
18 March 2021 - Seqirus announced that Health Canada has approved Flucelvax Quadrivalent (influenza vaccine), its cell-based quadrivalent influenza vaccine, for ...